The occurrence of deaths from second malignancy and cardiovascular disease which account for the majority of these (9; G-CSF vs 2; control) are of particular interest as it is now apparent from large epidemiologic analyses of NHL databases that long-term NHL survivors are at increased risk from these treatment-related complications. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.